Labiotech.eu

News and Trends 5 Oct 2022

OncoSec slashing staff numbers to prioritize pipeline

OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation. Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses. The company and remaining employees will focus clinical activities in melanoma […]

October 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract

Intravacc has been awarded a contract with base and options that may total US$14.6 million for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). The contract has been awarded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Gonorrhea is a sexually […]

October 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

CanSinoBIO to present latest data on inhaled COVID vaccine

CanSino Biologics Inc. will be presenting clinical trial data for the recombinant COVID-19 vaccine (adenovirus type 5 vector) for inhalation (with the trade name Convidecia Air) at World Vaccine Congress (WVC) Europe to be held October 11 to 14, 2022 in Barcelona, Spain. Jean-Denis Shu, vice president for medical affairs of CanSino Biologics will be […]

October 5, 2022 - 2 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 5 Oct 2022

Araris Biotech closes $24M financing round for ADCs

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the Institute for Follicular […]

October 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies

TrialSpark has announced a new partnership with global pharma company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently. The collaboration will focus on jointly pursuing the acquisition/in-licensing and development of best-in-class, clinical-stage phase II and phase III drug candidates in areas of high unmet patient need. The partnership […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

ASPIRE set up to collaborate on amyloidosis

A new group of biotech and pharma companies has been assembled by the Amyloidosis Research Consortium (ARC). ASPIRE (amyloidosis stakeholder partnerships for impact reach and equity), is a collaboration between biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients. […]

October 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Aeglea BioTherapeutics updates homocystinuria program

Aeglea BioTherapeutics, Inc. says dosing in the third cohort of the phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria is under way. Patients in this cohort are receiving 1.35 mg/kg of pegtarviliase once weekly administered via subcutaneous injection; patients in cohorts 1 and 2 received doses of 0.15 mg/kg and 0.45 […]

October 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Absolute Biotech launches as unified antibody company

Absolute Biotech has launched as a unified company to join antibody-centric brands from around the world. Absolute Biotech specializes in antibody reagents and services, adding value to existing antibodies, reagents and kits through annotation, validation, sequencing, engineering and recombinant manufacturing. The combined company will leverage each brand’s antibody expertise to advance the creation and availability […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Spinoff Biohaven launches with $258M and “incredible pipeline”

Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric as […]

October 4, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria

Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines. Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Ginkgo Bioworks acquires Altar and Circularis

Ginkgo Bioworks has announced the acquisition of two biotech companies, Altar, a French firm with a proprietary adaptive evolution platform, and Circularis, which has a proprietary circular RNA and promoter screening platform. Altar acquisition A fleet of Altar’s automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo’s Foundry to serve customers across food and […]

October 4, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

HumanFirst launches industry’s largest decentralized clinical trial database

HumanFirst has launched two new versions of the Atlas platform designed specifically for researchers in industry (AtlasPro) and academia (AtlasEDU). Atlas was created by HumanFirst to unlock better research for all humans sooner, and has been used for planning and deployment of trustworthy hybrid and at-home clinical trials by 22 of the 25 largest pharmaceutical […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

OncoSec slashing staff numbers to prioritize pipeline

Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract

CanSinoBIO to present latest data on inhaled COVID vaccine

Araris Biotech closes $24M financing round for ADCs

TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies

ASPIRE set up to collaborate on amyloidosis

Aeglea BioTherapeutics updates homocystinuria program

Absolute Biotech launches as unified antibody company

Spinoff Biohaven launches with $258M and “incredible pipeline”

Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria

Ginkgo Bioworks acquires Altar and Circularis

HumanFirst launches industry’s largest decentralized clinical trial database

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!